Oncology clinical trials are becoming harder to execute as precision medicine increases protocol complexity, narrows eligibility criteria and fragments patient populations. This webinar explores how operational gaps across sites, sponsors and CROs can slow screening, enrollment and study delivery, and why a more coordinated model is needed to keep pace with scientific progress.
From the medical oncologist’s perspective, biomarker-driven therapies are reshaping trial eligibility around narrower molecular subtypes, fresh tissue requirements and more complex endpoints. From the site perspective, limited screening infrastructure, inconsistent genomic testing and fragmented referral pathways make recruitment less predictable. From the sponsor and CRO perspective, disconnected data systems, inefficient screening funnels and high screen failure rates can delay enrollment and strain study timelines.
By examining these challenges across the oncologist, site, sponsor, CRO and patient experience perspectives, this session will highlight practical ways to improve patient identification, site readiness and data connectivity in oncology clinical trials. Attendees will gain a clearer view of how stronger operational design can support faster, more reliable trial execution at scale.
Register for this webinar to learn how stronger operational models can improve oncology clinical trials.
Speakers
(Moderator) Dannelle Palmer, MBA, Chief of Staff, Humaneva
Dannelle Palmer has three decades of global clinical development experience in pharmaceuticals, biotechnologies and global CRO organizations, leading clinical research teams with an emphasis on enhancing the performance and efficiency of oncology clinical research. Dannelle’s expertise and experience range from clinical development planning and regulatory consulting to leading studies from first-in-human through FDA and EMA approval. For the past 15 years, she has held executive-level positions focused on portfolio leadership, strategic leadership and customer-relationship development.
Message Presenter
Scott Schliebner, Chief Operating Officer, P1 Pratia Oncology
Scott is a strategic, innovative and commercially-focused Life Sciences Executive with 30+ years of experience across the biopharma, CRO and life sciences sectors. He thrives while building, transforming and growing clinical research organizations and life sciences companies. With a rare combination of strategic vision, commercial acumen and hands-on operational execution, Scott is an inspirational leader and force multiplier.
Mr. Schliebner currently serves as Chief Operating Officer at P1 Pratia Oncology, the first global, early-phase and community-based oncology site network. As a Strategic Advisor and Board Member, he also supports early-stage firms leveraging AI-driven platforms and technologies to disrupt and accelerate the clinical drug development process. He regularly speaks on topics such as patient-focused drug development, innovative clinical strategies, novel approaches to clinical development and global drug development market trends. Scott received a Master’s Degree in Public Health from the University of Utah School of Medicine and completed a Graduate Research Fellowship at the National Institutes of Health/NINDS.
Message Presenter
Dr. Julio A. Peguero, President and Executive Chairman, P1 Pratia Oncology; Medical Director of Research, Oncology Consultants, Houston
Dr. Julio A. Peguero is a board-certified Medical Oncologist and Internal Medicine Physician based in Houston, Texas. He serves as Medical Director of Research at Oncology Consultants and President and Executive Chairman of P1 Pratia Oncology, a community-focused early-phase oncology clinical research network. He earned his Medical Degree from Universidad Autónoma de Guadalajara. Dr. Peguero completed his Internal Medicine residency at the University of Texas Dell Medical School and completed his Medical Oncology fellowship at the University of Texas Medical Branch at Galveston and MD Anderson Cancer Center.
He has served as Principal Investigator in more than 200 clinical trials, including first-in-human studies, and his research has been presented and published at leading conferences and journals in oncology and hematology. He is an early advocate for next-generation sequencing and precision medicine, with a strong commitment to advancing cancer care through innovative research. In addition to his clinical and research leadership, he is dedicated to mentoring and training future physicians through academic and hands-on educational programs.
Message Presenter
Dr. Brandon Fletcher, Medical Affairs, Kapadi
Brandon Fletcher serves as both the Head of Medical Affairs and Cell- and Gene Therapy for Kapadi, the leading academic-based CRO for immuno-oncology and cell & gene therapies. Brandon has served in the industry for 32 years, with a deep focus on immune-oncology cell and gene therapeutics for the past 30 years. She is an adept and empowering leader with expertise in setting innovative strategic direction, medical/scientific currency, education/training, program building, team building and program and project management. She brings adaptable and actionable expertise and pluripotent industry savvy from multiple academic, hospital, biotech and CRO settings. Brandon is a Biochemist, Drug Development Specialist and Cancer Immunologist by education and training. She was an original collaborator with the NCI’s origination of cancer cell and gene therapeutics and has continued in the field of immune-oncology and genetically modified cell therapeutics since. She co-founded a global philanthropic organization that supports and trains investigators in underserved countries. In addition to her role in Medical Affairs, managing strategy, design and medical/science validity investigator relations, Brandon has served in extensive roles as the sponsor, drug development consultant, protocol writer and in project management and medical science oversight.
Message Presenter
Melanie Marshall, Associate Director, Data Quality Management, Kapadi
Melanie Marshall is a Clinical Research leader with 15 years of experience across biometrics and data quality, including more than 10 years in people and functional leadership roles. In her current role at a global CRO, she provides strategic oversight of RBQM, Central Data Monitoring and cross‑functional data quality initiatives to deliver inspection‑ready, high‑quality clinical trial data across global programs. With deep experience in oncology and a reputation for solving complex problems, she is dedicated to improving how clinical trial data is managed, analyzed and trusted.
Message PresenterWho Should Attend?
This webinar will appeal to:
- Early-Phase Biotech Leaders developing oncology assets
- Clinical Development teams planning first-in-human, Phase I or Phase I/II studies.
- Translational and Biomarker Strategy teams working to define patient selection and eligibility
- Regulatory and Medical Affairs professionals supporting oncology trial design and execution
- Program and Portfolio Managers evaluating clinical readiness and operational feasibility
- Operations and Study Start-Up teams looking to improve site activation and enrollment
- Clinical Operations Leaders working to identify patients faster and reduce screening failure
- CEOs, CDOs and Founders seeking a practical view of how to execute precision oncology studies more efficiently
- Anyone involved in bringing a biomarker-driven oncology program from design to first patient in, and beyond
What You Will Learn
Attendees will gain insight into:
- Why operational gaps have become a major barrier in oncology clinical trials
- How biomarker-driven eligibility makes patient identification and enrollment more difficult
- Where sites face the greatest operational challenges in screening and recruitment
- How disconnected data systems contribute to screen failures and trial delays
- What should a more coordinated model for oncology clinical trials include
Xtalks Partner
Humaneva (Kapadi)
Kapadi, a Humaneva Company, is a leading oncology CRO, offering comprehensive, custom-curated solutions to biotech companies ready to move their oncology and cell & gene assets from concept to clinic. Our team of oncology, IO, and CGT experts is ready to take your innovative ideas from concept to market, empowering you to make a real impact in the fight against cancer.
Partnered with the leading global site networks, Kapadi can access patients in an unprecedented way across the industry.
With a global footprint and unparalleled expertise, Kapadi can help you navigate regulatory pathways, enter the clinic successfully, and simplify complex trial operations. With custom-curated solutions ranging from consulting and FSP to full-service support, our bespoke solutions can support your clinical trials from Phase I to IV.
Leveraging technology and innovation, our teams apply analytics to their daily activities to optimize operations, accelerate decision-making, and drive your research program forward.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account